Search PubMed⌕ Search

PubMed · 2687794

Enzyme-replacement therapy: problems and prospects.

Abstract

Several diseases can, at least in theory, be treated by the administration of an enzyme, the deficiency of which is the cause of the disease. Various attempts have been made to correct enzymatic deficiencies responsible for the clinical manifestation of diseases for which prevention cannot be achieved by modification of the diet or by supportive therapy with drugs. Except for treating certain digestive disorders, enzyme-replacement therapy has not yet found a broad application. In this review article a compilation is given of the problems and prospects of enzyme-replacement therapy in diseases caused by the deficiency of an enzyme.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

B Rademaker, J Raber. 1989-10-20. Enzyme-replacement therapy: problems and prospects.. https://doi.org/10.1007/bf01959460

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

Saccadic analysis for early identification of neurological involvement in Gaucher disease.

The early identification of a neurological involvement in Gaucher's Disease (GD) is essential for a correct dosage of the enzymatic therapy. The saccadic eye movement characteristics of 15 patients affected by the non-neurological GD form show normal peak velocity values and some slight alterations of the velocity profiles present in more than 70% of the recorded eye movements in four cases; two of them later developed epilepsy. This fact supports the hypothesis that the presence of alterations in the velocity profile of the most part of saccadic movements is an index of initial neurological involvement. Further evaluations are necessary in order to understand if an increase of therapy dose should be used in all the subjects presenting such saccadic alterations.

Enzyme Therapy↗

Enzyme replacement and enhancement therapies for lysosomal diseases.

Although first suggested by de Duve in 1964, enzyme replacement therapy (ERT) for lysosomal storage diseases did not become a reality until the early 1990s when its safety and effectiveness were demonstrated in type 1 Gaucher disease. Today, ERT is a reality for Gaucher disease, Fabry disease and mucopolysaccharidosis type I (MPS I), and clinical trials with recombinant human enzymes are ongoing in Pompe disease, MPS II and MPS VI, and are about to begin in Neimann-Pick B disease. In addition to ERT, enzyme enhancement therapy (EET) offers a novel therapeutic strategy to increase the residual function of mutant proteins. EET employs small molecules as 'pharmacological chaperones' to rescue misfolded and/or unstable mutant enzymes or proteins that have residual function. EET also offers the possibility of treating neurodegenerative lysosomal disorders since these small therapeutic molecules may cross the blood-brain barrier. The current status of ERT and the prospects for EET for lysosomal storage diseases are reviewed.

Enzyme Therapy↗